Signaturefd, LLC Supernus Pharmaceuticals, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 561 shares of SUPN stock, worth $21,794. This represents 0.0% of its overall portfolio holdings.

Number of Shares

561

Previous 561 -0.0%

Holding current value

$21,794

Previous $15,000 13.33%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$25.99 - $33.85 $2,495 - $3,249	-96 Reduced 14.61%	561 $15,000
Q1 2024 May 03, 2024	SELL	$27.11 - $35.17 $189 - $246	-7 Reduced 1.05%	657 $22,000
Q4 2023 Jan 31, 2024	BUY	$22.72 - $29.68 $5,021 - $6,559	221 Added 49.89%	664 $19,000
Q3 2023 Nov 03, 2023	BUY	$27.57 - $32.91 $606 - $724	22 Added 5.23%	443 $12,000
Q2 2023 Aug 01, 2023	SELL	$29.91 - $38.73 $957 - $1,239	-32 Reduced 7.06%	421 $12,000
Q1 2023 Apr 28, 2023	SELL	$34.93 - $42.03 $69 - $84	-2 Reduced 0.44%	453 $16,000
Q3 2022 Nov 08, 2022	BUY	$28.79 - $35.41 $4,606 - $5,665	160 Added 54.24%	455 $15,000
Q2 2022 Aug 10, 2022	BUY	$25.33 - $34.25 $101 - $137	4 Added 1.37%	295 $9,000
Q4 2020 Feb 11, 2021	SELL	$17.7 - $25.81 $601 - $877	-34 Reduced 10.46%	291 $7,000
Q3 2020 Nov 03, 2020	BUY	$20.2 - $25.05 $3,999 - $4,959	198 Added 155.91%	325 $7,000
Q2 2020 Jul 30, 2020	BUY	$17.09 - $24.89 $2,170 - $3,161	127 New	127 $3,000
Q1 2020 Apr 23, 2020	SELL	$14.45 - $24.69 $274 - $469	-19 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$37.15 - $46.9 $705 - $891	19 New	19 $1,000

Others Institutions Holding SUPN

# of Institutions

289

Shares Held

60.8M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.08B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account